Buy $18 PT at Wainwright | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  2779 of 2852  at  9/6/2019 8:26:33 AM  by

Leverage01


 In response to msg 2778 by  KJDedge
view thread

Re: Buy $18 PT at Wainwright

Here it is :)

H.C. Wainwright analyst Swayampakula Ramakanth started Corcept Therapeutics (CORT) with a Buy rating and $18 price target. While the Street has been primarily focused on the quarterly sales of Korlym and the outcome of the ongoing patent lawsuit case against Teva Pharmaceuticals (TEVA), the primary driver of Corcept's long-term value lies in its product pipeline, Ramakanth tells investors in a research note. The analyst believes that by 2030, all of Corcept's revenues will be derived from its pipeline products and could reach $1.06B per year.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 212
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...